Cargando…

Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy

BACKGROUND: The efficacy of first-line chemoradiotherapy for overall survival (OS) might be confounded by the subsequent treatments in patients with locally advanced non-small cell lung cancer (NSCLC). In this study, we assessed the associations of progression-free survival (PFS) and post-progressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imai, Hisao, Kobayashi, Daijiro, Kaira, Kyoichi, Kawashima, Sayaka, Masubuchi, Ken, Murata, Masumi, Ebara, Takeshi, Kitamoto, Yoshizumi, Minato, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122299/ https://www.ncbi.nlm.nih.gov/pubmed/35218691 http://dx.doi.org/10.2478/raon-2022-0006

Ejemplares similares

Course of postoperative relapse in non‐small cell lung cancer is strongly associated with post‐progression survival
por: Imai, Hisao, et al.
Publicado: (2021)

Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations
por: Imai, Hisao, et al.
Publicado: (2021)

Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors
por: Imai, Hisao, et al.
Publicado: (2019)

Clinical significance of post‐progression survival in lung cancer
por: Imai, Hisao, et al.
Publicado: (2017)

Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study
por: Imai, Hisao, et al.
Publicado: (2021)

Clinical impact of post‐progression survival on overall survival in elderly patients with extensive disease small‐cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2016)

Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide
por: Imai, Hisao, et al.
Publicado: (2016)

Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study
por: Kotake, Mie, et al.
Publicado: (2019)

Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival
por: Masubuchi, Ken, et al.
Publicado: (2022)

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors
por: Miura, Yosuke, et al.
Publicado: (2017)

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
por: Kasahara, Norimitsu, et al.
Publicado: (2015)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
por: Imai, Hisao, et al.
Publicado: (2017)

Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis
por: Imai, Hisao, et al.
Publicado: (2018)

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
por: Wasamoto, Satoshi, et al.
Publicado: (2023)

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
por: Shiono, Ayako, et al.
Publicado: (2022)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients
por: Imai, Hisao, et al.
Publicado: (2022)

Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma
por: Imai, Hisao, et al.
Publicado: (2019)

A Th1-like CD4(+) T-cell Cluster That Predicts Disease-free Survival in Early-stage Lung Cancer
por: Yanagihara, Akitoshi, et al.
Publicado: (2023)

Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma
por: Imai, Hisao, et al.
Publicado: (2020)

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
por: Saito, Satoshi, et al.
Publicado: (2020)

Prognostic value of morphological characteristics assessed by CT scan in patients with non‐small cell lung cancer treated with nivolumab
por: Minemura, Hiroyuki, et al.
Publicado: (2020)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
por: Mouri, Atsuto, et al.
Publicado: (2021)

Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment
por: Kasahara, Norimitsu, et al.
Publicado: (2020)

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2017)

Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
por: Imai, Hisao, et al.
Publicado: (2015)

A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer
por: Kamiya, Teruhiko, et al.
Publicado: (2023)

Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non–small-cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2019)

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3r9fspkeg94b8srrou8k1587g8